Table 18, Summary of included studies. Comparison 17. Switching to a different SSRI versus continuing same SSRI - Further-line treatment

Warning: The NCBI web site requires JavaScript to function. more...

Study	Population	Intervention	Comparison	Details of inadequate response/treatment resistance	Comments
Nakajima 2011 RCT Japan	N=41 Mean age (years): 47.5 Gender (% female): 41 Ethnicity (% BME): NR Baseline severity: MADRS 30.49 (more severe)	Paroxetine 20-40mg/day	Sertraline 50-100mg/day	Inadequate response (HAMD score improvement <20%) after 2 weeks of treatment with sertraline	Treatment length (weeks): 6 Outcomes: Remission Response Discontinuation due to any reason Discontinuation due to side effects

Study

Population

Intervention

Comparison

Details of inadequate response/treatment resistance

Comments

RCT

Japan

N=41

Mean age (years): 47.5

Gender (% female): 41

Ethnicity (% BME): NR

Baseline severity: MADRS 30.49 (more severe)

Paroxetine 20-40mg/day

Sertraline 50-100mg/day

Inadequate response (HAMD score improvement <20%) after 2 weeks of treatment with sertraline

Treatment length (weeks): 6

Outcomes:

: BME: black and minority ethnic; HAMD: Hamilton depression scale; MADRS: Montgomery-Asberg depression rating scale; NR: not reported; RCT: randomised controlled trial; SSRI: selective serotonin reuptake inhibitor

Further-line treatment: Depression in adults: Evidence review D.

NICE Guideline, No. 222.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.